Evia HF (-T): the world’s first magnetic resonance approved pace-maker for resynchronization therapy

MRI is a widely accepted diagnostic tool with unparalleled soft-tissue imaging capabilities. Most importantly,nowadays, MRI has been successfully used to evaluate myocardial structure, wall motion, perfusion andviability and it may, therefore, become a first-choice diagnostic technique for heart failure. Unfortunately,the presence of cardiac electronic devices (e.g., pacemakers and defibrillators) in patients is currentlyconsidered a contraindication for MRI, and consequently hinders access to MRI for a large portion ofpatients that could benefit from it. The Evia HF(-T) device (BIOTRONIK SE & Co. KG, Berlin, Germany) isthe first pacemaker with the cardiac resynchronization therapy function for the treatment of ventriculardyssynchrony in heart failure patients that can be safely used in MRI (but not in cardiac magnetic resonance)under specific conditions. It completes the portfolio of magnetic resonance-conditional cardiac devicesnow available. The scope of this article is to describe the technical and clinical profile of this system in itsup-to-date context.